Published on
August 11, 2026
- 12:30 GMT
USPTO Issues Foundational Patent for Leptin Replacement in Anorexia Nervosa, Exclusively Licensed to Zula Therapeutics
Method-of-use patent gives Zula an exclusive position in leptin replacement for anorexia nervosa BOSTON, MA, UNITED STATES, August 11, 2026 /EINPresswire.com/ -- Zula Therapeutics, Inc. today announced that the United States Patent and Trademark Office …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
